Mian, Hira http://orcid.org/0000-0003-1584-1067
Wildes, Tanya M.
Venner, Christopher P.
Fonseca, Rafael http://orcid.org/0000-0002-5938-3769
Article History
Received: 22 May 2023
Revised: 10 October 2023
Accepted: 27 October 2023
First Online: 8 November 2023
Competing interests
: HM: Honoraria: BMS, Janssen, Abbvie, Pfizer, Forus, GSK, Sanofi, Amgen, Takeda. CPV: Honoraria: BMS, Janssen, Abbvie, Pfizer, Forus, GSK, Sanofi. RF: Consulting: AbbVie, Adaptive Biotechnologies, AMGEN, AZeneca, Bayer, Binding Site, BMS (Celgene), Millenium Takeda, Jansen, Juno, Kite, Merck, Pfizer, Pharmacyclics, Regeneron, Sanofi; Scientific Advisory Boards: Adaptive Biotechnologies, Caris Life Sciences, Oncotracker; Board of Directors: Antegene (for profit), AZBio (not for profit); patent for FISH in MM—~$2000/year.